查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1376007

重症肌无力治疗市场规模、份额、趋势分析报告：依治疗类型、最终用途、地区、细分市场趋势，2023-2030 年

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), By End-use (Hospitals, Clinics), By Region and Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

重症肌无力治疗市场的成长与趋势：

Grand View Research 的最新报告显示，到 2030 年，全球重症肌无力治疗市场预计将达到 42.6 亿美元。

预计 2023 年至 2030 年年复合成长率将达到 9.0%。人们对罕见疾病的认识不断提高、生技药品的出现以及免疫疗法和免疫抑制剂的日益普及正在推动重症肌无力 (MG) 治疗市场的发展。

重症肌无力 (MG) 是一种罕见的自体免疫疾病，由抗体介导的神经肌肉传递受损引起，导致骨骼肌无力。与这种疾病相关的疾病包括上眼睑下垂、复视、行走困难和说话困难。重症肌无力患者会出现无痛性肌无力，重复使用会加重肌无力，休息后会改善。

根据美国罕见疾病组织 (NORD) 的数据，美国每 10 万人中就有 14 至 40 人患有重症肌无力。报告表明，近几十年来，重症肌无力的发生率一直在增加。这是因为识别患者很容易，而且全世界一般人群中自自体免疫疾病的盛行率不断增加。重症肌无力在女性中比男性更常见，任何年龄均可出现症状，但症状发作通常在 50 至 60 岁之间的男性和 20 至 30 岁之间的女性中达到高峰。

在治疗领域，药物治疗占据最大的市场占有率，预计在预测期内将保持其市场主导地位。这是因为药物治疗可以在很大程度上控制症状并显着抑制免疫系统。药物包括免疫疗法，如 Soliris（依库丽单抗）、皮质类固醇和免疫抑制剂，如 Prograf（他克莫司）和 Neoral/Sundimmune（环孢素）。然而，新兴和欠发达国家的高治疗成本和低认识预计将阻碍市场成长。

重症肌无力治疗市场的成长与趋势：

  • 药物可以显着抑制免疫系统并在很大程度上抑制相关症状。药物包括免疫疗法，如 Soliris（依库丽单抗）、皮质类固醇和免疫抑制剂，如 Prograf（他克莫司）和 Neoral/Sundimmune（环孢素）。
  • 由于重症肌无力治疗的高精度和卓越疗效，单株抗体细分市场在2022年占据最大市场占有率，超过60%，预计在预测期内将保持主导地位。
  • 根据最终用途，市场分为医院、诊所等。 2022 年，医院细分市场占据最大市场占有率，约为 55%，预计在预测期内将以 9.0% 的复合年复合成长率成长。
  • 到 2022 年，北美市场占有率最大，超过 50%，预计将在整个预测期内引领市场。
  • 由于免疫抑制剂和单株抗体等医药产品的收益增加，预计亚太地区在预测期内将以有利的年复合成长率成长。

目录

第1章调查方法与范围

第2章执行摘要

第3章重症肌无力治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 重症肌无力治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章重症肌无力治疗：治疗类型的估计与趋势分析

  • 重症肌无力治疗市场：重点
  • 重症肌无力治疗市场：2022 年和 2030 年趋势和市场占有率分析
  • 胆碱酯酶抑制剂
    • 2018年至2030年胆碱酯酶抑制剂市场估计与预测
  • 慢性免疫调节剂
    • 2018年至2030年慢性免疫调节剂市场估计与预测
  • 单株抗体
    • 2018年至2030年单株抗体市场预测
  • 快速免疫治疗
    • 2018年至2030年快速免疫治疗市场估计与预测
  • 切除术
    • 2018年至2030年胸腺切除术市场估计与预测
  • 其他的
    • 2018 年至 2030 年其他市场估计与预测

第5章重症肌无力治疗：最终用途估计与趋势分析

  • 重症肌无力治疗市场：重点
  • 重症肌无力治疗市场：2022 年和 2030 年趋势和市场占有率分析
  • 医院
  • 诊所
  • 其他的

第6章重症肌无力治疗市场：区域估计与趋势分析

  • 区域展望
  • 按地区分類的重症肌无力治疗市场：主要市场点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第7章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Alexion Pharmaceutical Inc.
    • Grifols SA
    • Avadel Pharmaceuticals, Plc.
    • Novartis
    • Pfizer, Inc.
    • AbbVie Inc.
    • F.Hoffmann-La Roche AG
    • GlaxoSmithKline Plc.
    • Bausch Health Companies Inc.
    • Shire plc
Product Code: GVR-4-68038-002-6

Myasthenia Gravis Treatment Market Growth & Trends:

The global myasthenia gravis treatment market size is expected to reach USD 4.26 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 9.0% from 2023 to 2030. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Myasthenia Gravis Treatment Market Growth & Trends:

  • Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine).
  • The monoclonal antibodies segment held the largest market share of over 60% in 2022 and is expected to maintain its leading position through the forecast period, owing to the high precision in treating myasthenia gravis and better efficacy.
  • Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share of around 55% in 2022 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period.
  • In 2022, North America had the largest market share of over 50% and is projected to lead the market throughout the forecast period.
  • Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment Type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Myasthenia Gravis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Myasthenia Gravis Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Myasthenia Gravis Treatment: Treatment Type Estimates & Trend Analysis

  • 4.1. Myasthenia Gravis Treatment Market: Key Takeaways
  • 4.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Cholinesterase Inhibitors
    • 4.3.1. Cholinesterase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Chronic Immunomodulators
    • 4.4.1. Chronic immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Monoclonal Antibodies
    • 4.5.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Rapid Immunotherapies
    • 4.6.1. Rapid immunotherapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Thymectomy
    • 4.7.1. Thymectomy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Myasthenia Gravis Treatment: End Use Estimates & Trend Analysis

  • 5.1. Myasthenia Gravis Treatment Market: Key Takeaways
  • 5.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Clinics
    • 5.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Myasthenia Gravis Treatment Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Alexion Pharmaceutical Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Grifols SA
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Avadel Pharmaceuticals, Plc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Novartis
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Pfizer, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AbbVie Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F.Hoffmann-La Roche AG
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. GlaxoSmithKline Plc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Bausch Health Companies Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Shire plc
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 3 North America myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 4 North America myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 6 U.S. myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 8 Canada myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 10 Europe myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 13 Germany myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 15 UK myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 17 France myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 19 Italy myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 21 Spain myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Sweden myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 23 Sweden myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Norway myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 25 Norway myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Denmark myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 27 Denmark myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 31 China myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 32 China myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 34 Japan myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 36 India myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 38 Australia myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Thailand myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 40 Thailand myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 South Korea myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 42 South Korea myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 44 Latin America myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 Latin America myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 47 Brazil myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico myasthenia gravis treatment market, by treatment, type 2018 - 2030 (USD Million)
  • Table 49 Mexico myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 51 Argentina myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa myasthenia gravis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 56 South Africa myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 60 UAE myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait myasthenia gravis treatment market, by treatment type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait myasthenia gravis treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Myasthenia gravis treatment: Market outlook
  • Fig. 9 Myasthenia gravis treatment: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Myasthenia gravis treatment market driver impact
  • Fig. 15 Myasthenia gravis treatment market restraint impact
  • Fig. 16 Myasthenia gravis treatment market strategic initiatives analysis
  • Fig. 17 Myasthenia gravis treatment market: Treatment type movement analysis
  • Fig. 18 Myasthenia gravis treatment market: Treatment type outlook and key takeaways
  • Fig. 19 Cholinesterase inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic immunomodulators market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Rapid immunotherapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Thymectomy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myasthenia gravis treatment market: End use movement analysis
  • Fig. 26 Myasthenia gravis treatment market: End use outlook and key takeaways
  • Fig. 27 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Global myasthenia gravis treatment market: Regional movement analysis
  • Fig. 31 Global myasthenia gravis treatment market: Regional outlook and key takeaways
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)